CN1273173C - New use of medicine for preventing and treating radiative damage - Google Patents

New use of medicine for preventing and treating radiative damage Download PDF

Info

Publication number
CN1273173C
CN1273173C CN 02134695 CN02134695A CN1273173C CN 1273173 C CN1273173 C CN 1273173C CN 02134695 CN02134695 CN 02134695 CN 02134695 A CN02134695 A CN 02134695A CN 1273173 C CN1273173 C CN 1273173C
Authority
CN
China
Prior art keywords
radiation
medicine
root
group
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 02134695
Other languages
Chinese (zh)
Other versions
CN1421243A (en
Inventor
刘宗潮
陈小君
曾益新
张蓓
徐伯平
夏云飞
赵充
陈建业
陈效莲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV
Original Assignee
TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV filed Critical TUMOR PREVENTION AND THERAPY CENTER ZHONGSHAN UNIV
Priority to CN 02134695 priority Critical patent/CN1273173C/en
Publication of CN1421243A publication Critical patent/CN1421243A/en
Application granted granted Critical
Publication of CN1273173C publication Critical patent/CN1273173C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a new purpose of a medicine for treating and preventing radiation injury. The medicine is prepared from figwort root, rehmannia root, ophiopogon root, isatis root, oldenlandia, raw astragalus root, glossy privet fruit, lucid ganoderma and green tea by a certain proportion. The present invention can lower the mortality of mice irradiated by a lethal dose of radiant rays, improve the life quality of mice and increase the immune functions of tumor-bearing mice, and the present invention has synergic antitumor effects with radiant rays.

Description

Be used for the treatment of purposes with prevention radiation injury medicine
[technical field]
The present invention relates to a kind of being used for the treatment of and the purposes of preventing the radiation injury medicine.
[background technology]
Radiation claims lonizing radiation again, and radiation therapy claims radiotherapy again.Radiotherapy is one of main means of treatment of cancer, and many cancer patients can obtain curing with radiotherapy, but the staff who accepts the patient of radiation cure or contact radiation for a long time also can be subjected to the infringement or the damage of radiation, toxic and side effects occurs.People are seeking radioprotectant for a long time, but do not find out the toxic and side effects due to treatment of an ideal medicine usefulness and the prevention radiation so far yet.
Theory of Chinese medical science thinks that lonizing radiation belong to the heresy of pyretic toxicity, and tumour patient easily causes body body fluid impaired after accepting radiotherapy, and pyretic toxicity is crossed Sheng.Disharmony between QI and blood, taste imbalance and caused by liver and kidney deficiency appear in severe patient.Xerostomia, pharyngalgia, mucous membrane of oropharynx and skin ulceration can appear, symptoms such as tired power, spontaneous perspiration.Therefore, to the toxicity due to the radiation moisturize to promote the production of body fluid, heat-clearing and toxic substances removing, help that cold fills blood, medicine among the nourishing the liver and kidney.
[summary of the invention]
The invention provides a kind of being used for the treatment of and the application that prevents the radiation injury medicine, the composition of this medicine and the component of each composition are:
Radix Scrophulariae 8-14, Radix Rehmanniae 8-14, Radix Ophiopogonis 8-14, Radix Isatidis 6-10, Herba Hedyotidis Diffusae 5-9, Radix Astragali 7-11, Fructus Ligustri Lucidi 7-11, Ganoderma 5-7, green tea 2-4.
The invention provides a kind of Chinese medicine preparation, be used for the treatment of radiation according to due to toxicity;
The present invention shows by mouse experiment, can effectively reduce mortality of mice behind the lethal dose irradiation with radiation, improves life quality;
The present invention experiment showed, with tumor-bearing mice can not offset the killing effect of radiation to tumor cell, on the contrary, with radiation the synergistic antitumor effect is arranged;
The present invention experiment showed, the immunologic function that can improve tumor-bearing mice and plays antitumor action with tumor-bearing mice;
The present invention presses body surface area and calculates, 10 times of personnel selection consumptions; Press kilogram weight and calculate 100 times of dose singles of personnel selection consumption to observing 7 days behind the mouse stomach, mice has no poisoning manifestations.It is inferior on every Saturdays that the present invention gavages rat with two dosage of height, in continuous 12 weeks, bone marrow and hepatic and renal function do not had any toxicity damage.
[specific embodiment]
Be medicine of the present invention (trade name is radiation recovery oral liquid or capsule, tablet, pill, Emulsion, the dissolved granule) testing data relevant below with function.
One: the making of radiation health preparation
Choose superior Radix Scrophulariae 11 gram, the Radix Rehmanniae 11 grams, Radix Ophiopogonis 11 gram, Radix Isatidis 8 grams, Herba Hedyotidis Diffusae 7 grams, Radix Astragali 9 grams, Fructus Ligustri Lucidi 9 grams, Ganoderma 6 grams, green tea 3 grams, soaked 1-2 hour, execute water-bath and decoct, water-bath is concentrated into the 2.5g/ml crude drug, uses for zoopery.
Two: the radiation health is to the protective effect of irradiation with radiation animal
Method: get 100 individual weight 18-22 gram Kunming mouse, be divided into 5 groups, 20 every group.Do not make irradiation with radiation, gavage normal saline for the 1st group.The 2-5 group is accepted single 7.5Gy's (lethal dose) respectively 60The total irradiation of Co gamma-rays.The 2nd group gavages normal saline subsequently, and the 3rd, 4,5 group gavages basic, normal, high radiation recovery oral liquid respectively, every day 1 time, and continuous 30 days, observe and write down ordinary circumstance and the dead animal number of animal, calculate the protection index by following formula:
The result:
Table 1 radiation health is to the protective effect of irradiation with radiation animal
Group Dosage g/kg Observe 30 days survival rate The The average survival time natural law (X ± SD) K The P value
The laboratory animal number The live animal number is arranged Survival rate (%)
The matched group list is put 1 group of group radiation health *2 groups of radiation health *3 groups of radiation health * 30ml(NS) 30ml(NS) 37.18 52.5 75.0 20 20 20 20 20 20 0 9 10 14 100 0 45 50 70 30±0 12.5±8.1 21.5±8.9 20.9±9.6 24.8±8.3 - - 1.73 1.68 1.99 - - <0.01 <0.01 <0.01
*Medicament protection group: add after radiation shines and use the radiation health
Three: the collaborative anti-tumor effect of radiation health and radiation
Method: get 7-9 days rat liver cancer ascitic type ascites of growth under aseptic condition, (cell content is about 10 * 10 to become cell suspension with physiological water by 1: 1 dilution proportion 6Individual/ml) at the approaching right armpit subcutaneous vaccination 0.2ml of every Mus.Be divided into 4 groups after the inoculation at random.Every group 20, the 1st group of negative matched group do not made irradiation with radiation, gavages NS every day, totally 10 days; Do not make irradiation with radiation for the 2nd group, gavage the radiation health every day 1 time, totally 10 times; The 3rd group of usefulness 60CO gamma-rays total irradiation 1.5Gy per two days 1 time, totally 5 times, gavages NS every day 1 time, totally 10 times; The 4th group of usefulness 60CO gamma-rays total irradiation 1.5Gy, per two days 1 time, totally 5 times.Add every day with the radiation health and gavage totally 10 times 1 time.Put to death animal on the 11st day, and stripped out the tumor piece and weigh, calculate every group of average tumor body weight, calculate tumour inhibiting rate (IR) by following formula
The result:
The collaborative anti-tumor effect of table 2 radiation health and radiation
Group Drug dose (g/g) Number of animals Body weight (g) Average tumor is heavy Tumour inhibiting rate (%) The P value
Beginning The result Beginning The result
1 2 3 4 30ml NS 75 30ml NS * 75 * 20 20 20 20 18 20 20 20 21.5 21.4 21.4 21.5 28.0 28.3 22.3 23.4 2.14 1.07 0.74 0.392 - 50.0 65.4 81.7 - <0.01 <0.01 <0.01
*Accept 60Co radiation gamma 1.5Gy * 5 times
Four: the antitumaous effect of radiation health and centralizing function
Method: get 7-9 days rat liver cancer ascitic type ascites of growth under aseptic condition, (cell content is about 10 * 10 to become cell suspension with normal saline by 1: 1 dilution proportion 6Individual/ml) at the approaching right armpit subcutaneous vaccination 0.2ml of every Mus.Be divided into negative control group after the inoculation at random, basic, normal, high three the dosage groups of radiation health.Gastric infusion after 24 hours, every day 1 time, continuous 10 days.Drug withdrawal 24 hours is got blood from the eye chamber, surveys the T lymhocyte transformation rate, puts to death animal subsequently, strips out spleen, thymus and tumor piece, calculates tumour inhibiting rate (IR) by following formula
The result:
Table 3 radiation health is to the inhibitory action of rat liver cancer
Group Dosage (g/kg) Number of animals Body weight change (g) On average seriously ill (X ± SD) Press down sick rate (%) The P value
Before After
3 groups of 2 groups of radiation health of 1 group of radiation health of NS matched group radiation health 30ml 37.8 52.5 75.0 13 13 13 13 13 13 13 13 +7.9 +6.7 +7.6 +8.3 1.37±0.49 0.67±0.29 0.65±0.23 0.60±0.20 - 51.1 52.6 56.2 - <0.01 <0.01 <0.01
Table 4: the radiation health is to the influence of tumor-bearing mice body weight, spleen weight, thymus weight, spleen index and thymus index
Group Body weight (g) Spleen heavy (mg) The P value Thymus heavy (mg) The P value Spleen index The P value Thymus index The P value
Before After
3 groups of 2 groups of radiation of 1 group of radiation of NS radiation 22.4±0.8 22.6±0.9 22.9±0.9 22.5±1.0 30.3±3.9 29.4±3.1 30.6±2.4 30.7±1.9 148.5±45.3 141.2±23.4 17.0±51.1 18.3±72.1 >0.05 >0.06 >0.05 56.9±14.8 80.8±12.1 82.1±21.1 87.0±15.0 - <0.001 <0.001 <0.001 4.9 4.9 5.6 6.0 - >0.05 >0.05 >0.05 1.9 2.7 2.7 2.8 - <0.001 <0.001 <0.001
Annotate: numeral is the meansigma methods of every group of 13 animals in the table
Table 5 radiation health is to the influence of tumor-bearing mice lymhocyte transformation rate
Group Dosage (g/kg) Lymphocyte transformation (%) (n=13, x ± SD) The P value
3 groups of 2 groups of radiation health of 1 group of radiation health of NS radiation health 30ml 37.8 52.5 75.0 24.22±16.89 47.16±16.87 48.07±25.57 50.86±22.19 - <0.01 <0.01 <0.01

Claims (1)

1, the application of a kind of pharmaceutical preparation in the medicine of preparation treatment and prevention radiation injury is characterized in that described pharmaceutical preparation made by the following weight proportion raw material: Radix Scrophulariae 8-14, Radix Rehmanniae 8-14, Radix Ophiopogonis 8-14, Radix Isatidis 6-10, Herba Hedyotidis Diffusae 5-9, Radix Astragali 7-11, Fructus Ligustri Lucidi 7-11, Ganoderma 5-7, green tea 2-4.
CN 02134695 2002-09-07 2002-09-07 New use of medicine for preventing and treating radiative damage Expired - Fee Related CN1273173C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 02134695 CN1273173C (en) 2002-09-07 2002-09-07 New use of medicine for preventing and treating radiative damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 02134695 CN1273173C (en) 2002-09-07 2002-09-07 New use of medicine for preventing and treating radiative damage

Publications (2)

Publication Number Publication Date
CN1421243A CN1421243A (en) 2003-06-04
CN1273173C true CN1273173C (en) 2006-09-06

Family

ID=4747846

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 02134695 Expired - Fee Related CN1273173C (en) 2002-09-07 2002-09-07 New use of medicine for preventing and treating radiative damage

Country Status (1)

Country Link
CN (1) CN1273173C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105148038A (en) * 2015-10-28 2015-12-16 粘琦玉 Traditional Chinese medicine pills for treating adverse reactions after CT examination and preparation method

Also Published As

Publication number Publication date
CN1421243A (en) 2003-06-04

Similar Documents

Publication Publication Date Title
CN105816430A (en) Preparation method of radix tetrastigme polysaccharide particle with antitumor function
CN1305515C (en) Chinese medicine powder and decoction composition for treating cancers
CN102579803B (en) Medicine for treating post-chemotherapy leucopenia and preparation method thereof
CN101711848A (en) Chinese medicinal composition capable of adjunctively treating tumour
CN1302798C (en) Medicine for preventing and treating radiative damage
CN100336552C (en) Medicine for treating lung cancer
CN1273173C (en) New use of medicine for preventing and treating radiative damage
CN108186794A (en) A kind of Chinese medicine composition for treating malignant tumour and its preparation method and application
CN102078600B (en) Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same
CN1857605A (en) Medicine for treating chronic alcoholic hepatopathy and its preparing method
CN112220846A (en) Traditional Chinese medicine composition for treating children's chronic cough and application thereof
CN106619870B (en) Composition for treating digestive system tumor and preparation method thereof
CN1824156A (en) Chinese medicine mixed preparation for treating stomach precancer and its preparation method
CN1723956A (en) Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method
CN113244204B (en) Application of zingiberenone A in preparation and/or application of zingiberenone A as product for enhancing body immunity
CN114831312B (en) Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof
CN103800844B (en) A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof
CN1042495C (en) Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn.
CN107596013A (en) A kind of extracting method of maca and its male health-care product of preparation
CN101007114B (en) An adjuvant drug or health food for tumor patients and preparation thereof
CN1836674A (en) Antler lucid ganoderma and its extract for preparing pharmaceutical and food for treating cancer and immunity effect
Huanga et al. Clinical Observation of the Dispelling Turbid Qi and Stopping Nausea and Vomit Decoction in Prevention of Nausea and Vomiting in Chemotherapy with Cisplatin
CN1186680A (en) High effect nontoxic natural anti-cancer agent
CN100488550C (en) Combination of medication for enhancing functions of the liver and the stomach, and preparation method
CN104473946A (en) Pharmaceutical composition used for treating leukemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060906

Termination date: 20100907